Serving To Educate Primary Care Clinicians On Metabolic Issues
Evidence Based Medicine Header 1
Medical Education Header 2
Peer-to-peer Exchange Header 3
Metabolic Diseases Header 4
News: Prescriber's Letter August 2015
 ANTITHROMBOTICS

You'll see LESS use of "bridging" with low-molecular-weight heparin (enoxaparin, etc) in warfarin patients
   Up to 1 in 6 patients are bridged with an injectable anticoagulant when warfarin is temporarily stopped before surgery or a procedure...hoping to prevent thrombosis or stroke. 
   But evidence from the new BRIDGE trial will be a game changer. It suggests that bridging does more harm than good in many patients. 

For the most recent full article AND to access all of the benefits of Prescriber's Letter subscribe to an option below:

Prescriber's Letter offers PCMG Members a 10% discount at two subscription levels:

The Gold Subscription is $129 and includes CME

The Platinum Subscription is $189 and provides enhanced CME and Live Webinar access 

Enter Discount Code PCMG15 when ordering either subscription HERE